Oral lactoferrin as a treatment of pediatrics’ anemia resulted from chronic kidney diseases: a randomized controlled trial
Abstract Anemia in pediatrics is often associated with chronic conditions such as chronic kidney disease (CKD). It can worsen the disease prognosis and affect quality of life. Injectable dosage forms are predominantly used in its treatment with various side effects. This randomized and parallel clin...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-88506-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823862459108163584 |
|---|---|
| author | Sahar Kamal Hegazy Mai Salah El-Din Koura Mohamed Shokry Elharoun |
| author_facet | Sahar Kamal Hegazy Mai Salah El-Din Koura Mohamed Shokry Elharoun |
| author_sort | Sahar Kamal Hegazy |
| collection | DOAJ |
| description | Abstract Anemia in pediatrics is often associated with chronic conditions such as chronic kidney disease (CKD). It can worsen the disease prognosis and affect quality of life. Injectable dosage forms are predominantly used in its treatment with various side effects. This randomized and parallel clinical trial aimed to compare the effectiveness of oral lactoferrin with intravenous (IV) iron dextran in managing anemia resulted from CKD in pediatrics. The study involved 60 children diagnosed with CKD-related anemia who were allocated into two separate groups. Group 1 consisted of 30 pediatric patients who received 100 mg of oral lactoferrin daily for a period of 3 months. Group 2 included 30 pediatric patients who were given IV iron dextran at a dosage of 50 mg three times weekly for 3 months. Both treatments are effective in treating CKD-induced anemia in pediatrics; however, oral lactoferrin demonstrated superior efficacy as there was a significant change within that group in levels of Hb, RBCs, MCH, iron, RDW-SD, MCHC, IL-6, and GDF-15 before and after treatment. In contrast, IV iron dextran showed significant changes within its group in iron, GFR, IL-6, GDF-15, and RDW-SD. After 3 months of treatment, no significant differences were observed between the two groups. |
| format | Article |
| id | doaj-art-18403688922f4a4496ad11767418febd |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-18403688922f4a4496ad11767418febd2025-02-09T12:29:43ZengNature PortfolioScientific Reports2045-23222025-02-011511810.1038/s41598-025-88506-2Oral lactoferrin as a treatment of pediatrics’ anemia resulted from chronic kidney diseases: a randomized controlled trialSahar Kamal Hegazy0Mai Salah El-Din Koura1Mohamed Shokry Elharoun2Professor of Clinical Pharmacy-Faculty of Pharmacy, Tanta UniversitySenior Critical Care Clinical Pharmacy, Menoufia University Hospitals, MSc in pharmacy, Faculty of Pharmacy, Tanta UniversityLecturer of Pediatrics-Faculty of Medicine, Menoufia UniversityAbstract Anemia in pediatrics is often associated with chronic conditions such as chronic kidney disease (CKD). It can worsen the disease prognosis and affect quality of life. Injectable dosage forms are predominantly used in its treatment with various side effects. This randomized and parallel clinical trial aimed to compare the effectiveness of oral lactoferrin with intravenous (IV) iron dextran in managing anemia resulted from CKD in pediatrics. The study involved 60 children diagnosed with CKD-related anemia who were allocated into two separate groups. Group 1 consisted of 30 pediatric patients who received 100 mg of oral lactoferrin daily for a period of 3 months. Group 2 included 30 pediatric patients who were given IV iron dextran at a dosage of 50 mg three times weekly for 3 months. Both treatments are effective in treating CKD-induced anemia in pediatrics; however, oral lactoferrin demonstrated superior efficacy as there was a significant change within that group in levels of Hb, RBCs, MCH, iron, RDW-SD, MCHC, IL-6, and GDF-15 before and after treatment. In contrast, IV iron dextran showed significant changes within its group in iron, GFR, IL-6, GDF-15, and RDW-SD. After 3 months of treatment, no significant differences were observed between the two groups.https://doi.org/10.1038/s41598-025-88506-2Chronic kidney diseasePediatricsAnemiaLactoferrinIV iron dextran |
| spellingShingle | Sahar Kamal Hegazy Mai Salah El-Din Koura Mohamed Shokry Elharoun Oral lactoferrin as a treatment of pediatrics’ anemia resulted from chronic kidney diseases: a randomized controlled trial Scientific Reports Chronic kidney disease Pediatrics Anemia Lactoferrin IV iron dextran |
| title | Oral lactoferrin as a treatment of pediatrics’ anemia resulted from chronic kidney diseases: a randomized controlled trial |
| title_full | Oral lactoferrin as a treatment of pediatrics’ anemia resulted from chronic kidney diseases: a randomized controlled trial |
| title_fullStr | Oral lactoferrin as a treatment of pediatrics’ anemia resulted from chronic kidney diseases: a randomized controlled trial |
| title_full_unstemmed | Oral lactoferrin as a treatment of pediatrics’ anemia resulted from chronic kidney diseases: a randomized controlled trial |
| title_short | Oral lactoferrin as a treatment of pediatrics’ anemia resulted from chronic kidney diseases: a randomized controlled trial |
| title_sort | oral lactoferrin as a treatment of pediatrics anemia resulted from chronic kidney diseases a randomized controlled trial |
| topic | Chronic kidney disease Pediatrics Anemia Lactoferrin IV iron dextran |
| url | https://doi.org/10.1038/s41598-025-88506-2 |
| work_keys_str_mv | AT saharkamalhegazy orallactoferrinasatreatmentofpediatricsanemiaresultedfromchronickidneydiseasesarandomizedcontrolledtrial AT maisalaheldinkoura orallactoferrinasatreatmentofpediatricsanemiaresultedfromchronickidneydiseasesarandomizedcontrolledtrial AT mohamedshokryelharoun orallactoferrinasatreatmentofpediatricsanemiaresultedfromchronickidneydiseasesarandomizedcontrolledtrial |